长春瑞滨联合卡铂治疗老年晚期非小细胞肺癌

Clinical observation of vinorelbine and carboplatin in treating elder advanced non-small cell lung cancer

目的：观察长春瑞滨加卡铂联合化疗治疗老年晚期非小细胞肺癌患者的临床疗效和毒副反应.方法：对24例≥70岁的老年晚期非小细胞肺癌患者采用长春瑞滨联合卡铂方案化疗：长春瑞滨25mg/m^2,静脉滴注,第1、8天;卡铂AUC=4～5,静脉滴注,第2天,每3周重复,至少治疗2周期.结果：共完成63周期,中位数3周期,有效率33.33%,中位生存期10.25个月,1年生存率41.67%.主要毒副反应为骨髓抑制,发生率83.33%,其中I度8.33%,Ⅱ度41.67%,Ⅲ度29.17,Ⅳ度4.17%.结论：长春瑞滨联合卡铂方案治疗老年晚期非小细胞肺癌有较好疗效,毒副反应可以耐受.

Objective：To evaluate the clinical efficacy and side effects of combination chemotherapy with vinorelbine plus carboplatin in elder patients with advanced non-small cell lung cancer（NSCLC）. Methods：Twenty-four elder patients （ ≥ 70years） with unresectable NSCLC were enrolled into this study. Vinorelbine was administered 25mg/m^2 on days 1 and 8 and carboplatin AUC =4 - 5 on day 2 intravenously every 3 weeks and with at least 2 cycles. Results：63 cycles of the chemotherapy were completed and the median cycles of the treatment were 3. The response rate was 33. 33%, median survival time was 10. 25 months and 1 year survival rate was 48.40%. The main toxicity was myelosuppression, which account for 83.33% of the patients. The grade Ⅰ , Ⅱ, Ⅲ and Ⅳ was 8.33% ,41.67% ,29. 17% and 4. 17%, respectively. Conclusion： The schedule of vinorelbine and carboplatin for eider advanced NSCLC has good clinical efficacy and tolerability.